Scilex Holding (SCLX) Payables (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Payables of $101.6 million for Q1 2026, up 77.41% year-over-year from $57.3 million in Q1 2025, and up 17.75% on a QoQ basis from $86.3 million in Q4 2025.
Scilex Holding (SCLX) Payables (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Payables for 7 consecutive years, with $101.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 77.41% year-over-year to $101.6 million; the TTM figure through Mar 2026 stood at $101.6 million (up 77.41% YoY), while the FY2025 annual figure was $86.3 million, up 63.94% from the prior year.
- Payables came in at $101.6 million for Q1 2026 at Scilex Holding, up from $86.3 million in the prior quarter.
- The five-year high for Payables was $101.6 million in Q1 2026, with the low at $41003.0 in Q1 2022.
- Average Payables over 5 years is $30.8 million, with a median of $9.8 million recorded in 2023.
- Across the five-year window, Payables plunged 99.67% in 2022 and soared 53473.08% in 2024, its largest moves.
- Year by year, Payables stood at $79000.0 in 2022, then jumped by 254.43% to $280000.0 in 2023, then surged by 18692.86% to $52.6 million in 2024, then soared by 63.94% to $86.3 million in 2025, then increased by 17.75% to $101.6 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $101.6 million, $86.3 million, and $68.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.03 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 27.92 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.77 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -22.55 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 101.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.58 Mn |
| Dec 31, 2025 | 86.27 Mn |
| Sep 30, 2025 | 68.16 Mn |
| Jun 30, 2025 | 59.16 Mn |
| Mar 31, 2025 | 57.26 Mn |
| Dec 31, 2024 | 52.62 Mn |
| Sep 30, 2024 | 346,000.00 |
| Jun 30, 2024 | 41.79 Mn |
| Mar 31, 2024 | 42.22 Mn |
| Dec 31, 2023 | 280,000.00 |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 78,000.00 |
| Mar 31, 2023 | 9.82 Mn |
| Dec 31, 2022 | 79,000.00 |
| Sep 30, 2022 | 809,292.00 |
| Jun 30, 2022 | 598,646.00 |
| Mar 31, 2022 | 41,003.00 |
| Dec 31, 2021 | 23.89 Mn |
| Sep 30, 2021 | 43,569.00 |
| Jun 30, 2021 | 20,025.00 |